Renal transplantation

Current Opinion in Urology

Volumn 9, Issue 2, 1999, Pages 121-127

  Barry, John M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PURINE ANTAGONIST; TACROLIMUS;

ALOPECIA; CADAVER DONOR; CADAVER KIDNEY; CONCEPTION; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; ECHOGRAPHY; GASTROINTESTINAL TOXICITY; GINGIVA HYPERPLASIA; HEALTH CARE POLICY; HIRSUTISM; HISTOCOMPATIBILITY; HUMAN; HYPERCHOLESTEROLEMIA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LAPAROSCOPIC SURGERY; LEUKOPENIA; LIVING DONOR; MORBIDITY; NEPHRECTOMY; NEPHROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; REVIEW; SPIRAL COMPUTER ASSISTED TOMOGRAPHY; TECHNIQUE; TREMOR; UROGRAPHY;

ANIMALS; FEMALE; GRAFT REJECTION; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; PREGNANCY; TISSUE DONORS;

EID: 0032996633     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-199903000-00006     Document Type: Review

References (37)

1. Barry JM. Renal transplantation. In: Campbell's urology. Walsh PC, Retik AB, Vaughan ED, Wein AJ (editors). Philadelphia: WB Saunders Co.; 1990. pp. 506-530.
2. Taylor RJ, Murillo D. Renal transplantation: surgical aspects, complications, and results. Curr Opin Urol 1998; 8:135-140.
3. United States Renal Data System Executive Summary. Am J Kidney Dis 1998; 32(Suppl 1):S9-S19. The Executive Summary reviews the incidence and prevalence of end-stage renal disease, treatment modalities for end-stage renal disease patients, patient mortality and survival, renal transplantation outcomes, pediatric end-stage renal disease, costs of end-stage renal disease and international comparison of end-stage renal disease therapy.
4. Cecka JM. The UNOS scientific renal transplant registry: ten years of kidney transplants. In: Clinical transplants 1997. Cecka JM, Terasaki PI (editors). Los Angeles: UCLA Tissue Typing Laboratory; 1998. pp. 1-14. Documents the 10 years of progress in kidney transplantation in the USA.
5. Terasaki Pl, Cho YW, Cecka JM. Strategy for eliminating the kidney shortage [Editorial]. In: Clinical transplants, 1997. Cecka JM, Terasaki PI (editors). Los Angeles: UCLA Tissue Typing Laboratory; 1998. pp. 265-267. This article provides the reader with an intriguing solution to the shortage of transplantable kidneys.
6. Terasaki PI, Cecka JM, Gjertson DW, Cho YW. Spousal and other living renal donor transplants. In: Clinical Transplants, 1997. Cecka JM, Terasaki Pl (editors). Los Angeles: UCLA Tissue Typing Laboratory; 1998. pp. 269-284.
7. Radcliffe-Richards J, Daar AS, Guttmann RD, Hoffenberg R, Kennedy I, Lock M, et al. The case for allowing kidney sales. Lancet 1998; 351:1950-1952. I really like this one. We were quietly considering developing a paid donor program in a Middle Eastern country when the Western transplantation community decided that anyone participating in such a 'Scheme' would be ejected from the transplantation societies, and we quietly abandoned the concept.
8. LuL. Commerce in organ transplantation. Pharos. 1998; 61:2-5.
9. Panico M, Solomon M, Burows L. Issues of informed consent and access to extended donor poof kidneys. Transplant Proc 1997; 29:337-338. This article discusses informed consent and extended donor cadaver kidney transplants. The discussion is a good one.
10. Cho YW, Terasaki PI, Cecka JM, Gjertson DW. Transplantation of kidneys from donors whose hearts have stopped beating, N Engl J Med 1998; 338:221-225.
11. Daemen JHC, deVries B, Kootstra G. The effect of machine perfusion preservation on early function of non-heart-beating donor kidneys. Transplant Proc 1997; 29:3489.
12. Whiting JF, Golconda M, Smith R, O'Brien S, First MR, Alexander JW. Economic costs of expanded criteria donors in renal transplantation. Transplantation 1998; 65:204-207.
13. Roels L, Roelants M. Timmermans T, Hoppenbrowers K, Pillen E, Bande-Knops J. A survey on attitudes to organ donation among three generations in a country with ten years of presumed consent legislation. Transplant Proc 1997; 29:3224-3225.
14. Platt JF, Ellis JH, Korobkin M, Reige K. Helical CT evaluation of potential kidney donors: findings in 154 subjects. Am J Roentgenol 1997; 169:1325-1339.
15. Low RN, Martinez AG, Steinberg SM, Alzate GD, Kortman KE, Bower BB, et al. Potential renal transplant donors: evaluation with gadolinium-enhanced MR angiography and MR urography. Radiology 1998; 207:165-172.
16. Flowers JL, Jacobs S, Cho E, Morton A, Rosenberger WF, Evans D, et al. Comparison of open and laparoscopic live donor nephrectomy. Ann Surg 1997; 226:483-489.
17. Philosophe B, Kuo PC, Schweitzer EJ, Farney AC, Lim JW, Johnson LB, Bartlett ST. Laparoscopic vs. open donor nephrectomy: comparing ureteral complications in the recipients and improving the laparoscopic technique [Abstract]. American Society of Transplant Surgeons, 24th Scientific Meeting, 1998; A-167.
18. Leow CK. Comment on 'Laparoscopic-assisted live donor nephrectomy - a comparison with the open approach'. Transplantation 1997; 64:1222. I liked this letter to the editor because it reflects my own concerns about laparoscopic donor nephrectomy.
19. Bar-Nathan N, Shmueli D, Yussim A, Lustig S, Eisenstein B, Davidovich M, et al. Alternative venous drainage for renal transplantation. Transplant Proc 1997; 29:2660-2661.
20. Indudhara R, Joseph DB, Perez LM, Diethelm AG. Renal transplantation in children with posterior urethral valves revisited: a 10-year follow-up. J Urol 1998; 160:1201-1203.
21. Fontaine E, Salomon L, Gagnadoux MF, Niaudet P, Broyer M, Beurton D. Long-term results of renal transplantation in children with the prune-belly syndrome. J Urol 1997; 158:892-894.
22. Gonzalez R. Renal transplantation into abnormal bladders [Editorial]. J Urol 1997; 158:895-896. This editorial outlines the principles of transplantation into abnormal bladders. I liked the editorial because I agreed with it.
23. Delpizzo JJ, Jacobs SC, Bartlett ST, Sklar GN. The use of bladder for total transplant ureteral reconstruction. J Urol 1998; 159:750-752. How many of these damaged ureters were from laparoscopically retrieved living donor kidney transplants?
24. Nicita G, Villari D, Marzocco M, Marzi VL, Trippitelli A, Santoro G. Endoluminal stent placement after percutaneous transluminal angioplasty in the treatment of post-transplant renal artery stenosis. J Urol 1998; 159:34-37.
25. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomized trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 1997; 350:1193-1198.
26. Charpentier B, Thervet E. Placebo-controlled study of humanized anti-TAC monoclonal antibody in dual therapy for the prevention of acute rejection after renal transplantation. Transplant Proc 1998; 30:1331-1332.
27. Burk ML, Matuszewski KA. Muromonab-CD3 and antithymocyte globulin in renal transplantation. Ann Pharmacother 1997; 31:1370-1377. This is a good review of the indications and results for antilymphocyte antibody therapy in kidney transplantation.
28. Spencer CM, Goa KL, Gillis JC. Tacrolimus: an update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 1997; 54:925-975. This is an excellent review of tacrolimus.
29. Morris-Stiff G, Richards T, Singh J, Baboolal K, Balaji V, Ostrowski K, et al. Pharmaco-economic study of FK506 (Prograf) and cyclosporine A (Neoral) in cadaveric renal transplantation Transplant Proc 1998; 30:1285-1286.
30. Matthew TH for the Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. A blinded, long-term, randomized multicenter study of FK506 (Prograf) and cyclosporine A (Neoral) in cadaveric renal transplantation. Transplant Proc 1998; 30:1285-1286. This is a good review of the relatively new immunosuppressant, mycophenolate mofetil.
31. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation 1997; 64:1277-1282.
32. Sullivan SD, Garrison Jr LP, Best JH. The cost of effectiveness of mycophenolate mofetil in the first year after primary cadaveric transplantation. J Am Soc Nephrol 1997; 8:1592-1598.
33. Szczeech LA, Berlin JA, Feldman HI. The effect of antilymphocyte induction therapy on renal allograft survival: a meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998; 128:817-826.
34. Newman JD. UNOS board-approved voluntary CREG protocol: alternate kidney matching system to be studied. UNOS Update 1998; Special Edition, Spring: 18-19.
35. Anonymous. Call for participants in UNOS voluntary local renal allocation variance using cross-reactive HLA antigen groups (CREGs). UNOS 1997; (distribution date 9 December 1997). pp. 1-14. This publication describes the rationale for HLA Crossreactive antigen group matching for cadaver kidney transplantation and its projected impact on cadaver kidney graft survival rates and the more equitable sharing of cadaver kidney grafts.
36. Davison JM, Milne JEC. Pregnancy and renal transplantation. Br J Urol 1997; 80 (Suppl 1): 29-32. This article outlines the risks of pregnancy after renal transplantation and describes the principles to help avoid complications in the mother and baby.
37. Armenti VT, Coscia LA, McGrory GH, Moritz MJ. National Transplantation Pregnancy Registry: update on pregnancy and renal transplantation. Nephrol News Issues 12:19-22.